SCHEMBL3339261

SCHEMBL3339261

COc1ccc(-c2nn3c(O)cc(C(S)c4cccc(F)c4F)nc3c2-c2ccccc2)cc1OC

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
ESR1 P03372 2/20 0.35
ESR2 Q92731 2/20 0.35
TDP1 Q9NUW8 2/20 0.35
CTSA P10619 2/20 0.35
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
TP53 P04637 1/20 0.35
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 2/20 0.34
HSD17B10 Q99714 2/20 0.34
FYN P06241 1/20 0.34
USP2 O75604 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3339262 0.78 CXCR2 (0.41) MAPTL3MBTL1ALDH1A1FYNTSHR
SCHEMBL3337240 0.72 KDM4E (0.37) MAPTTP53KDM4EHSD17B10TSHR
SCHEMBL3365721 0.72 NPC1 (0.34) MAPTTDP1TP53POLB
SCHEMBL3344951 0.70 ALDH1A1 (0.40) MAPTTDP1MEN1POLBKMT2A
SCHEMBL3344941 0.69 MEN1 (0.30) MEN1KMT2A
SCHEMBL3367417 0.69 L3MBTL1 (0.34) MAPTL3MBTL1TDP1TP53MEN1
SCHEMBL3340198 0.68 ACHE (0.31)
SCHEMBL3340932 0.68 PDE4D (0.32) MAPTPDE4D
SCHEMBL3339890 0.68 ALDH1A1 (0.39) L3MBTL1MEN1KMT2AALDH1A1HPGD
SCHEMBL3367911 0.68 TSHR (0.42) MAPTTP53POLBALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US claimed
US-20100152205-A1 CXCR2 INHIBITORS NOVARTIS AG 2010-06-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152205-A1 CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 MAPT 4670/4885L3MBTL1 4102/4885ESR1 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.